



European Prevention of Alzheimer's Dementia (EPAD)

- Policy and Standards for publication using EPAD LCS data and samples -

We encourage publication of any research arising from use of the EPAD data. If you publish results that were generated using the EPAD data and/or samples then we do request acknowledgement of this and the grants that supported EPAD. Further details are provided in this present document, which outlines the policies for publication and publication credits for those who use EPAD data and/or samples.

1. Scientific publications and presentations including EPAD data and/or samples

All forms of EPAD dissemination, including papers or presentations, containing information directly linked to the EPAD Longitudinal Cohort Study (LCS) must reference the clinicaltrials.gov EPAD LCS ID **NCT02804789**. In addition, each data set will have a DOI to reference the source of the data in subsequent publication (you can find further information about the data set and the DOI [here](#)).

This above information should be incorporated into the article or presentation based on the house style of the communication vehicle. For a paper, it is strongly recommended to include this above information in the methods section.

The articles and presentations generated using EPAD data and/or samples must include the following elements:

- EPAD LCS is registered at www.clinicaltrials.gov Identifier: NCT02804789.
- Data used in preparation of this article were obtained from the EPAD LCS data set Vx00x.x, doi:10.100/0xx. The EPAD LCS was launched in 2015 as a public-private partnership, led by Chief Investigator Professor Craig Ritchie MB BS. The primary research goal of the EPAD LCS is to provide a well-phenotyped probability-spectrum population for developing and continuously improving disease models for Alzheimer's disease in individuals without dementia.
- This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736 and an Alzheimer's Association Grant (SG-21-818099-EPAD).





2. Authorship

In the case of articles generated using EPAD data and/or samples, on the by-line of the manuscript, after the named authors, the following phrase must be included:

“for the European Prevention of Alzheimer’s Disease (EPAD) Consortium*” with the asterisk referring to the following statement:

“Data used in preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer’s Disease (EPAD) Consortium. As such investigators within the EPAD LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in analysis or writing of this report. A complete list of EPAD Investigators can be found at:

http://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf

3. Publications reporting

Regardless of what subset of data is used in publications, authors must inform EPAD about the planned communication, apprise EPAD of acceptance or rejection, provide a copy of the manuscript upon publication of the manuscript and provide URL to published work. Please contact info@ep-ad.org.

